1. Home
  2. CRSP vs ECG Comparison

CRSP vs ECG Comparison

Compare CRSP & ECG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CRSP
  • ECG
  • Stock Information
  • Founded
  • CRSP 2013
  • ECG 1995
  • Country
  • CRSP Switzerland
  • ECG United States
  • Employees
  • CRSP N/A
  • ECG N/A
  • Industry
  • CRSP Biotechnology: Biological Products (No Diagnostic Substances)
  • ECG
  • Sector
  • CRSP Health Care
  • ECG
  • Exchange
  • CRSP Nasdaq
  • ECG NYSE
  • Market Cap
  • CRSP 3.4B
  • ECG 3.5B
  • IPO Year
  • CRSP 2016
  • ECG N/A
  • Fundamental
  • Price
  • CRSP $47.87
  • ECG $43.58
  • Analyst Decision
  • CRSP Buy
  • ECG Strong Buy
  • Analyst Count
  • CRSP 21
  • ECG 2
  • Target Price
  • CRSP $75.42
  • ECG $73.50
  • AVG Volume (30 Days)
  • CRSP 2.7M
  • ECG 780.3K
  • Earning Date
  • CRSP 02-11-2025
  • ECG 02-11-2025
  • Dividend Yield
  • CRSP N/A
  • ECG N/A
  • EPS Growth
  • CRSP N/A
  • ECG N/A
  • EPS
  • CRSP N/A
  • ECG 2.81
  • Revenue
  • CRSP $37,314,000.00
  • ECG $2,849,685,000.00
  • Revenue This Year
  • CRSP $227.76
  • ECG $4.22
  • Revenue Next Year
  • CRSP $353.05
  • ECG $5.79
  • P/E Ratio
  • CRSP N/A
  • ECG $15.51
  • Revenue Growth
  • CRSP N/A
  • ECG N/A
  • 52 Week Low
  • CRSP $36.52
  • ECG $40.05
  • 52 Week High
  • CRSP $90.62
  • ECG $77.93
  • Technical
  • Relative Strength Index (RSI)
  • CRSP 58.27
  • ECG N/A
  • Support Level
  • CRSP $38.28
  • ECG N/A
  • Resistance Level
  • CRSP $55.88
  • ECG N/A
  • Average True Range (ATR)
  • CRSP 2.87
  • ECG 0.00
  • MACD
  • CRSP 1.07
  • ECG 0.00
  • Stochastic Oscillator
  • CRSP 54.50
  • ECG 0.00

About CRSP CRISPR Therapeutics AG

Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.

About ECG EVERUS CONSTRUCTION GROUP INC

Everus Construction Group Inc is a construction solutions provider, offering specialty contracting services to a diverse set of end markets across the U.S. It operates across two segments, Electrical & Mechanical (E&M) and Transmission & Distribution (T&D), and delivers services through its subsidiaries. It generates the majority of revenue from the Electrical & Mechanical segment which offers a wide variety of specialty contracting services, including construction and maintenance of electrical and communication wiring, fire suppression systems, and mechanical piping and services, to customers in both the public and private sectors. Its T&D segment serves electric and natural gas utility customers, as well as customers in the transportation end market, in the West and Midwest regions.

Share on Social Networks: